FDA Approves Mimrylo as First-in-Class Treatment for Rare Blood Cancer Polycythemia Vera

The U.S. Food and Drug Administration has approved Mimrylo (rusfertide), a first-in-class targeted therapy for polycythemia vera, a rare and chronic blood cancer. Developed by Protagonist Therapeutics and commercialized by Takeda, the once-weekly subcutaneous injection offers a highly anticipated alternative to the invasive treatments that have defined the disease's management for decades. Mimrylo is the first pharmaceutical product approved for the condition that directly mimics hepcidin, the body's natural iron-regulating hormone.[1][2][3]

Polycythemia vera affects approximately 90,000 Americans and is characterized by the bone marrow overproducing red blood cells. This overproduction thickens the blood, significantly elevating the risk of life-threatening cardiovascular events such as blood clots, strokes, and heart attacks. The primary goal of treatment is to maintain a patient's hematocrit—the proportion of red blood cells in the blood—below a safe threshold of 45 percent.[1][4][5]

For years, the standard of care has bordered on the medieval: patients frequently undergo therapeutic phlebotomy, a routine bloodletting procedure designed to manually remove excess red blood cells from circulation. While effective at lowering hematocrit, phlebotomy does not address the underlying disease mechanism and leaves many patients tethered to frequent clinic visits. According to Takeda, roughly 78 percent of patients fail to keep their hematocrit levels adequately controlled with existing standard treatments, which also include hydroxyurea and interferons.[1][3][4]

Mimrylo introduces a fundamentally new mechanism of action to the nonmalignant hematology space. By acting as a hepcidin mimetic, the drug restricts the availability of iron in the blood. Because iron is a necessary building block for red blood cells, limiting its supply essentially starves the bone marrow's excess production, keeping red blood cell levels in check without the need to physically drain blood from the patient's veins.[1][4][6]

The FDA's decision was heavily supported by data from the Phase 3 VERIFY trial, a double-blind, placebo-controlled study involving 293 adults with polycythemia vera who required frequent phlebotomies. The results were definitive: 76.9 percent of patients treated with Mimrylo required zero phlebotomies between weeks 20 and 32 of the study, compared to just 32.9 percent of those receiving a placebo.[1][2][3]

Beyond hematocrit control, the trial demonstrated meaningful improvements in quality of life. Patients on Mimrylo reported significant reductions in disease-related symptoms, most notably fatigue—a chronic complaint among those with polycythemia vera. The drug's safety profile was also favorable, with the most common adverse reactions being mild-to-moderate injection site reactions and anemia.[1][2]

The approval marks the culmination of a turbulent development journey for Protagonist Therapeutics. In 2021, the FDA placed rusfertide on a clinical hold after animal studies revealed skin tumors in mice, and the agency even threatened to revoke the drug's breakthrough therapy designation. Protagonist navigated the regulatory hurdles, eventually lifting the hold and securing a lucrative partnership with Takeda in 2024 to co-develop and commercialize the therapy.[3][5]

For Takeda, Mimrylo represents a major regulatory victory and a strategic expansion of its hematology portfolio. The company is projecting peak global sales in the range of $1 billion to $2 billion. While the exact list price has not yet been disclosed, Takeda executives have stated the pricing will reflect the drug's value while ensuring patient access. The medication is expected to be available to patients within 48 hours of the FDA's approval.[5]

The introduction of Mimrylo is expected to shift the treatment paradigm for polycythemia vera, moving clinical practice away from reactive symptom management and toward proactive disease regulation. By directly addressing the iron dysregulation that drives the disease's hallmark overproduction of red blood cells, the therapy offers patients a chance to reclaim their daily routines from the burden of chronic blood draws.[2][6]